These patients are normally aged between 25 and 45 years old, and end unable to work, with estimated healthcare costs and value loss of 3M€
the novel implantable biomaterial that promotes sensory and motor recovery following spinal cord injury.
the business model is based on supplying the device to healthcare providers, such as hospitals, clinics, and national health services.
Things are moving fast and we would like to keep you up to date with our progress. Sign up to stay in the loop.
By submitting my data I agree to be contacted